Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to Neutral at UBS Group

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities researchers at UBS Group from a “buy” rating to a “neutral” rating in a report issued on Thursday,Briefing.com Automated Import reports. They currently have a $738.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $1,130.00. UBS Group’s price objective points to a potential upside of 4.91% from the stock’s current price.

A number of other equities analysts have also recently weighed in on the company. Sanford C. Bernstein lowered their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, Bank of America restated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Stock Up 1.8 %

REGN stock opened at $703.43 on Thursday. The firm has a market cap of $77.30 billion, a PE ratio of 17.41, a PEG ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals has a one year low of $666.25 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm’s 50 day moving average price is $746.43 and its 200-day moving average price is $956.18.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of REGN. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Regeneron Pharmaceuticals by 4.8% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 24,319 shares of the biopharmaceutical company’s stock valued at $25,479,000 after acquiring an additional 1,122 shares in the last quarter. Argent Trust Co lifted its stake in shares of Regeneron Pharmaceuticals by 1.3% during the second quarter. Argent Trust Co now owns 2,370 shares of the biopharmaceutical company’s stock worth $2,491,000 after purchasing an additional 31 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 5.4% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,314 shares of the biopharmaceutical company’s stock worth $2,432,000 after buying an additional 119 shares during the period. MRP Capital Investments LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $306,000. Finally, Mark Sheptoff Financial Planning LLC grew its stake in shares of Regeneron Pharmaceuticals by 35.0% in the second quarter. Mark Sheptoff Financial Planning LLC now owns 135 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 35 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.